Roivant Sciences (NASDAQ:ROIV) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note published on Monday morning, Benzinga reports.

Several other research firms have also issued reports on ROIV. HC Wainwright restated a buy rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, August 19th. Piper Sandler boosted their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an overweight rating in a report on Wednesday, July 10th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $17.15.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $12.12 on Monday. The stock has a market capitalization of $8.95 billion, a P/E ratio of 2.40 and a beta of 1.25. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. Roivant Sciences has a 1-year low of $8.24 and a 1-year high of $13.24. The business has a 50-day moving average price of $11.31 and a two-hundred day moving average price of $11.04.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The business had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. During the same period in the prior year, the business posted ($0.38) earnings per share. Roivant Sciences’s revenue was up 155.1% compared to the same quarter last year. Equities analysts predict that Roivant Sciences will post -1.14 earnings per share for the current year.

Institutional Trading of Roivant Sciences

Several hedge funds and other institutional investors have recently modified their holdings of ROIV. nVerses Capital LLC acquired a new position in Roivant Sciences during the 2nd quarter worth approximately $34,000. Point72 Hong Kong Ltd bought a new stake in Roivant Sciences during the 2nd quarter worth about $36,000. Quarry LP acquired a new stake in shares of Roivant Sciences in the second quarter valued at about $53,000. Acadian Asset Management LLC acquired a new stake in shares of Roivant Sciences in the first quarter valued at about $72,000. Finally, Fifth Third Wealth Advisors LLC bought a new stake in Roivant Sciences during the second quarter worth about $101,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.